Third Quarter 2023 Report
November 6, 2023
OneTest Premium Launched; Improved Accuracy Over Competing circulating tumor DNA Tests
Last month we launched OneTest Premium an upgrade to the Standard version of OneTest with additional biomarkers and improved cancer prediction. In the first few weeks the majority of online purchasers chose the Premium version at a $269 list price versus $189 for OneTest Standard.

OneTest Premium detects more earlier stage cancers than the competing $949 Galleri test from Grail. In blinded studies conducted this year in 20/20's clinical lab using blood specimens from over 500 American and Western European cancer patients, 20/20's test detected over twice the number of stage 1 and more than 50% the number of stage 2 cancers than the Grail test at comparable specificities. (Data to be published; available upon request).

Click here to order OneTest Premium. For a 15% discount use coupon code: "November2023" (code valid through the end of this month)
20/20 Ranked #1 Fastest Growing Maryland Company on Inc.5000 List
This year's Inc. magazine list of the 5000 Fastest Growing Private Companies in America, which came out in August, ranked our company #1 for the State of Maryland, #7 for Health Products, and #134 overall. This ranking, based on revenue growth over 3 years, was mainly attributed to our high volume Covid lab testing between 2020 and 2022.
3Q Cancer Test Sales Up 60% Year-Over-Year
For the 3-month period ending September 30, OneTest sales totaled $220,000 compared to $135,000 for the same quarter in 2022. Over 50 new institutional customers have adopted this test so far this year, accounting for about 65% of sales in 2023. These customers include seven large occupational health groups, three corporate health and wellness companies, two health screening companies that offer OneTest (combined with full-body imaging), and 40 new fire departments.
Coming Soon: Convenient Fingerstick Version of OneTest at Pharmacies Nationwide
We have been in development of a version of OneTest that uses a fingerstick sample instead of requiring a traditional venous blood draw. Studies conducted by our research collaborators in Taiwan demonstrated that OneTest performs equally well. These equivalency studies now permit convenient access to our test at pharmacies nationwide and eventually at-home. Interest has been received from several national pharmacy chains.

Avoiding the need for phlebotomy will offer a substantial advantage over competing tests like Grail's Galleri that analyze circulating DNA which requires larger blood volumes.
MD Anderson & 20/20 Develop Economic Benefit Analysis for Congressional Budget Office
Earlier this year bipartisan legislation was re-introduced in the U.S. Congress to provide an expedited pathway for Medicare coverage of multi-cancer early detection (MCED) blood tests. (20/20's test is currently one of only two MCEDs actively marketed in the U.S. as of this writing.) Despite the fact that over half of the members of the House and Senate have signed on as co-sponsors of this bill, supported by the American Cancer Society and a host of other disease advocacy groups, the cost estimate by the non-partisan Congressional Budget Office (CBO) has posed a stumbling block towards passage. However, an economic analysis being prepared by a team from the MD Anderson Cancer Center suggests that widespread adoption of an MCED like 20/20's OneTest would result in a multi-billion-dollar surplus, not deficit. The bill's sponsors are hopeful that this analysis will positively impact the CBO cost score and will pave the way for passage in 2024.
20/20's Digital Marketing Director on the Front Lines with Fire & Rescue Services in Israel
Since October 7, our digital marketing director Eitan Charnoff has been serving with Israel's Fire and Rescue Services. Among his duties are to help coordinate a team of over 50 experienced American firefighters and EMS personnel who have been deployed to Israeli fire stations to substitute for those called up for military reserve duty. His important work on behalf of the Israel Emergency Volunteers Project is highlighted in this recent news story. In honor of Eitan and the American fire and rescue personnel now serving in Israel, please consider a donation to the Emergency Volunteers Project using this link.

Our previous Quarterly Reports and Press Releases may be downloaded here:
Financial Reports
In order to maintain our Reg. A+ Qualification we are required to file Annual and Semiannual Reports with the U.S. Securities & Exchange Commission (SEC) that include Financial Statements (the Annual Statement must be audited). Those reports may be accessed by entering "20/20 GeneSystems, Inc." at or by contacting [email protected]

Forward Looking Statements
This quarterly report to shareholders contains statements that do not relate to historical facts but are “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements can generally (although not always) be identified by their use of terms and phrases such as anticipate, appear, believe, continue, could, estimate, expect, indicate, intend, may, plan, possible, predict, project, pursue, will, would and other similar terms and phrases, as well as the use of the future tense. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on current beliefs, expectations and assumptions regarding the future of the business of the Company, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control, including the risks described in our offering statements and reports under the heading “Risk Factors” as filed with the SEC. Actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Forward-looking statements in this quarterly report to shareholders speak only as of the date hereof. Unless otherwise required by law, we undertake no obligation to publicly update or revise these forward-looking statements, whether because of new information, future events or otherwise.